There is a need for specific drugs to treat NASH. Lifestyles are rarely enough and for patients with advanced conditions this will not be sufficient. Several drugs with different mechanisms of action are in development to treat NASH. They are currently available only via protocols but this will change in the next few years. The challenge then will be to personalize the treatment.
This Perspective provides an overview on the development of knowledge related to nonalcoholic fatty liver disease with a focus on landmark findings that have influenced […]Read in full >
Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis. Harrison SA et al. Hepatology. 2019 Feb 25.Read in full >
Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis Ratziu […]Read in full >